Publication
Feifel D, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression. JAMA, 2026
DOI 10.1001/jama.2026.18380
Фаза 2b (NCT05870540), двойное слепое, 193 взрослых с резистентной депрессией, 38 центров. MADRS к 29-му дню: −11,1 против −5,5 (разница −5,3; 95% ДИ −8,9…−1,8). Ответ 34–35% против 12%. Спонсор Beckley Psytech.
Also in the catalogue
- ЛорундростатDrug
- Vacheron CH, et al. Influence of Preoperative Virtual Reality on Preoperative State Anxiety in the Ambulatory Setting: The AMBLUMEEN RCT. Anesth Analg, 2026Publication
- Yang Y, et al. SGLT2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: Meta-Analysis of RCTs. JAMA, 2026Publication
- Мебуфотенин (5-MeO-DMT, BPL-003)Drug
- Zhang Z, et al. Dynamic force sensing by bone delays aging and extends lifespan. Cell Metab, 2026Publication
- Watson SL, et al. High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. J Bone Miner Res, 2018Publication
Scales
Identifiers
- DOI
- 10.1001/jama.2026.18380
Original sources
Details
- Journal
- JAMA
- Year
- 2026
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.